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Extent of Lymphadenectomy and Prognosis
After Esophageal Cancer Surgery
Jesper Lagergren, MD, PhD; Fredrik Mattsson, BSc; Janine Zylstra, BSc; Fuju Chang, MD; James Gossage, MD;
Robert Mason, MD; Pernilla Lagergren, PhD; Andrew Davies, MD
IMPORTANCE The prognostic role of the extent of lymphadenectomy during surgery for
esophageal cancer is uncertain and requires clarification.
OBJECTIVE To clarify whether the number of removed lymph nodes influences mortality
following surgery for esophageal cancer.
DESIGN, SETTING, AND PARTICIPANTS Conducted from January 1, 2000, to January 31, 2014,
this was a cohort study of patients who underwent esophagectomy for cancer in 2000-2012
at a high-volume hospital for esophageal cancer surgery, with follow-up until 2014.
EXPOSURES Themain exposure was the number of resected lymph nodes. Secondary
exposures were the number of metastatic lymph nodes and positive to negative lymph node
ratio.
MAIN OUTCOMES ANDMEASURES The independent role of the extent of lymphadenectomy in
relation to all-cause and disease-specific 5-year mortality was analyzed using Cox
proportional hazard regressionmodels, providing hazard ratios (HRs) with 95% CIs. The HRs
were adjusted for age, pathological T category, tumor differentiation, margin status, calendar
period of surgery, and response to preoperative chemotherapy.
RESULTS Among 606 included patients, 506 (83.5%) had adenocarcinoma of the esophagus,
323 (53%) died within 5 years of surgery, and 235 (39%) died of tumor recurrence. The extent
of lymphadenectomywas not statistically significantly associated with all-cause or
disease-specific mortality, independent of the categorization of lymphadenectomy or
stratification for T category, calendar period, or chemotherapy. Patients in the fourth quartile
of the number of removed nodes (21-52 nodes) did not demonstrate a statistically significant
reduction in all-cause 5-year mortality compared with those in the lowest quartile (0-10
nodes) (HR, 0.86; 95% CI, 0.63-1.17), particularly not in themost recent calendar period (HR,
0.98; 95% CI, 0.57-1.66 for years 2007-2012). A greater number of metastatic nodes and a
higher positive to negative node ratio was associated with increasedmortality rates, and
these associations showed dose-response associations.
CONCLUSIONS AND RELEVANCE This study indicated that the extent of lymphadenectomy
during surgery for esophageal cancer might not influence 5-year all-cause or disease-specific
survival. These results challenge current clinical guidelines.
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E sophagealcancer is thesixthmostcommoncauseofcan-cer death globally,1 and the incidence of esophageal ad-enocarcinoma is increasingwhile theprognosis remains
poor(<15%5-yearsurvival).2Curatively intendedtreatmentwith
surgery, typicallyprecededbyoncological therapy,3offersa lim-
ited (30%) chance of 5-year survival.4,5 The optimal extent of
lymphadenectomyiscontroversial andrequiresclarification.5-9
Esophageal cancer spreads readily inamultidirectional fashion
through the extensive submucosal lymphatics that drain the
esophagus, andthepresenceofmetastatic lymphnodesare the
strongestknownprognostic factors.5This implies thatmoreex-
tensivelymphadenectomyshouldimprovesurvival.Ontheother
hand, it is still unclear whether themore extensive removal of
regional (metastaticornot)nodesactuallycontributestothecure
ofpatientswithesophageal cancer.There is apossible trade-off
between the potential survival benefit with more extensive
lymphadenectomyandadecreasedpostoperativemorbiditywith
less extensive lymphadenectomy.5-9 Although based on a lim-
itednumberofstudieswithmethodologicalconcernswithstage
migrationandconfounding, current clinical guidelines recom-
mend2-field (extensive) lymphadenectomy.6,7,10Yet, in routine
clinicalpractice, the limitedscientificknowledge leaves itup to
thediscretionof the individual surgeon todecide thepreferred
extentof lymphadenectomy.8,9Thepresentstudywasprompted
by the lackof survival benefit fromamoreextensive lymphad-
enectomyinourpopulation-basedSwedishcohortstudy.11Here,
weaimedto testwhether the resultsof thatprevious study rep-
licatedusinganotherdesignandbasedonanotherpopulation.
Weused a prospective and comprehensive clinical data collec-
tionfromahigh-volumesurgerycenter inLondon,England,with
surgeons andpathologists specialized in the fieldof esophage-
al cancer.
Methods
Study Design
This cohort study included all surgically treated patients with
esophagealcanceratahigh-volumecenterinLondon(StThomas’
Hospital)between2000and2012,with follow-upuntil January
2014.Anearlierversionof this cohorthasbeenused inprevious
publications.12,13 In brief, all operated-on patientswith esoph-
agealcancerwerefollowedupuntildeathortheendofthestudy,
whicheveroccurredfirst.Themainstudyexposurewasthenum-
berof removed lymphnodes. Secondary studyexposureswere
thenumberofmetastatic lymphnodesandtheratioofmetastatic
to total number of lymphnodes. The outcomeswere all-cause
anddisease-specific5-yearmortality.The5-yearcutoffwasused
because deaths occurring later are usually not due to tumor
recurrence.4Ethicalapprovalwasgrantedforuseofthedatabase
from the National Research Ethics Service, NRES Committee
NorthWest,Manchester, England.Patient consentwaswaived
bytheNationalResearchEthicsServicebecauseit isnotrequired
for database research.
Surgery
The main surgical approaches were transhiatal or transtho-
racic (open or minimally invasive) esophagectomy. The pre-
ferred esophageal substitute was gastric conduit, anasto-
mosed to theproximal esophagus in the thoraxorneck. There
were 3 consultant surgeons conducting the operations dur-
ing the study. Therewasno consensus about thepreferred ex-
tent of lymphadenectomy.
Histopathology
All resected tumors underwent careful review by a consul-
tant specializing inupper gastrointestinal histopathology. Tu-
mor stage was classified according to the 7th edition of the
American Joint Committee on Cancer TNM staging system.14
Pathologic tumor regression following preoperative chemo-
therapy was assessed according to the Mandard scoring sys-
tem, ranging from 1 (complete response) to 5 (no response).
In this study, the Mandard et al15 score was dichotomized, as
plannedapriori, intogood (scoresof 1-3)orpoor (scoresof4-5).
Statistical Analysis
Cox proportional hazard modeling was used to analyze asso-
ciations between the 3 lymphadenectomy exposure vari-
ables (totalnumberof lymphnodes,numberofpositive lymph
nodes, and ratio of positive and total number of lymphnodes)
and the 2 mortality outcomes (time to all-cause and disease-
specific mortality with 5 years of follow-up). The categoriza-
tionof the total number of removednodes intodecentiles and
quartileswas planned before any analyseswere initiated. Be-
cause there were no dose-response associations between the
total number of removed lymph nodes and mortality in the
analysis using decentiles, we found it inappropriate to ana-
lyze the total number of lymph nodes as an ordinal variable.
Thus, we only analyzed the total number of lymphnodes as a
categorical variable.
The current version of the N-coding system was used to
categorize the number of positive lymphnodes (0, 1-2, 3-6, or
>6).16 The ratio of positive and total number of lymph nodes
wascategorized into4groups (decidedbeforeanalyses),where
the 0 ratio was categorized into one group and the rest of the
data split into tertiles. The first group (lowest lymphnodehar-
vest, nometastatic nodes, andmetastatic tononmetastatic ra-
tio of 0) was used as the reference for all lymphadenectomy
variables.Hazard ratios (HRs)with95%CIswerederived from
themodel.Hazard ratioswerepresentedasunadjustedandad-
justed for 6 predefined potential confounding factors: (1) age
(continuous variable); (2) pathological T category (catego-
rized a priori into 2 groups: T0-T2 or T3-T4); (3) tumor grade
(3 groups: high-gradedysplasia andwell-differentiated,mod-
eratelydifferentiated, orpoorlydifferentiated); (4)margin sta-
tus (2 groups: R0 or R1/R2 [within 1 mm from the circumfer-
entialmargin]); (5) response topreoperative chemotherapy (3
groups: not applicable, good response [Mandard score 1-3], or
poor response [Mandard score 4-5]); and (6) calendar period
(2 groups: years 2000-2006 or 2007-2012).
Furthermore,we evaluatedwhether the adjustedHRs for
the lymphadenectomy variables were modified by T cat-
egory (T0-T2orT3-T4), calendar period (2000-2006or 2007-
2012), or response to chemotherapy (not applicable, good, or
poor) using a product term in the regressionmodels. TheHRs
and 95% CIs were derived by the HR statement in themodel.
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Furthermore, 9more variables were createdwith a combina-
tionofeach lymphadenectomyexposureandTcategory (T0-T2
orT3-T4), calendar period (2000-2006or 2007-2012), and re-
sponse to chemotherapy (not applicable, good,orpoor). These
stratified analyseswere conductedas apotential survival ben-
efit,withmoreextensivenoderemovalpotentiallybeinghigher
in more advanced tumors,17 as treatment might change over
calendar time and as chemotherapy and the response to it
might influenceanysurvivalbenefitsofmoreextensive lymph-
adenectomy. To manage partial missing data for Mandard
scores (5.3%of the patients hadmissing data), both complete
case analysis and multiple imputation were conducted. The
imputation variables were categorized as presented here and
includedage,pathologicalTcategory, tumorgrade,marginsta-
tus, responsetopreoperativechemotherapy,andall-causemor-
tality. The number of imputed data sets was 20 and mono-
tone logistic method in PROC MI was used under the
assumption that the missing data were missing at random.18
PROCMIANALYZE (SAS Institute Inc)wasused to combine the
results from the analyses of the 20 data sets. Because the re-
sults were similar between the 2 missing values approaches,
we decided to present only HRs and 95% CIs from the mul-
tiple imputation. To avoid influence of collinearity of the ex-
posure variables, these variables were analyzed separately
without adjusting for any of the others.
To validate the results, we performed a sensitivity analy-
sis by calculating propensity scores. Logistic regression with
generalized logit function was used with the total number of
lymph nodes in quartiles and the 6 covariates in the model.
The distribution of propensity score by outcome group was
similar. Thepropensity scoresdivided intoquintileswere then
used in the Cox proportional hazard model as a covariate by
eachpair of the total numberof lymphnodes comparison.The
datamanagementandstatistical analyseswereperformedwith
SAS version 9.4 (SAS Institute Inc).
Results
Patient Characteristics
The study included606patients,mostwith adiagnosis of ad-
enocarcinomaof the esophagus (n = 506; 83.5%),while fewer
patients had squamous cell carcinoma (15.2%) or adenosqua-
mous carcinoma (1.3%) of the esophagus. Characteristics of
these participants, in total and split into quartiles by the ex-
tentof lymphadenectomy,arepresented inTable 1.Among323
patients (53%) who died within 5 years of surgery, 235 (39%)
diedof tumor recurrence. The agedistributionwas similar be-
tweenpatients in the4 lymphadenectomycategories.Moread-
vancedTcategorieswereslightlyoverrepresented in thehigher
2quartiles of lymphadenectomy,whilewell-differentiated tu-
morsandtumorswithhigh-gradedysplasiaor completepatho-
logical response were overrepresented in the lower 2 quar-
tiles of lymphadenectomy. A higher proportion of patients
receivedpreoperative chemotherapyduring the last calendar
period (77% in 2000-2006) compared with the first calendar
Table 1. Characteristics of 606 PatientsWhoUnderwent Esophagectomy for Cancer in 2000-2012
Characteristic
No. (%)
Total Cohort
Total Lymph Nodes Removed in Quartiles [Range]
I [0-10] II [11-14] III [15-20] IV [21-52]
Total 606 (100) 166 (27) 139 (23) 151 (25) 150 (25)
5-y Mortality
All cause 323 (53) 87 (52) 69 (50) 86 (57) 81 (54)
Disease specific 235 (39) 67 (40) 52 (37) 59 (39) 57 (38)
Age, median (range), y 64 (29-83) 63 (29-80) 64 (38-83) 64 (34-83) 65 (32-81)
T category
T0-T2 311 (51) 90 (54) 77 (55) 72 (48) 72 (48)
T3-T4 295 (49) 76 (46) 62 (45) 79 (52) 78 (52)
Tumor differentiation
Wella 71 (12) 26 (16) 18 (13) 13 (9) 14 (9)
Moderate 331 (55) 85 (51) 75 (54) 92 (61) 79 (53)
Poor 204 (34) 55 (33) 46 (33) 46 (30) 57 (38)
Resection
R0 340 (56) 88 (53) 82 (59) 88 (58) 82 (55)
R1 or R2b 266 (44) 78 (47) 57 (41) 63 (42) 68 (45)
Mandard scorec
1, 2, or 3 163 (27) 36 (22) 35 (25) 41 (27) 51 (34)
4 or 5 196 (32) 28 (17) 50 (36) 58 (38) 60 (40)
NA 215 (35) 84 (51) 50 (36) 45 (30) 36 (24)
Missing 32 (5) 18 (11) 4 (3) 7 (5) 3 (2)
Calendar period
2000-2006 367 (61) 126 (76) 88 (63) 79 (52) 74 (49)
2007-2012 239 (39) 40 (24) 51 (37) 72 (48) 76 (51)
Abbreviation: NA, not applicable.
a This category includes tumors that
are well differentiated, high-grade
dysplasia, or complete pathological
response to preoperative
chemotherapy.
bCircumferential resectionmargin
less than 1 mm from the tumor.
c Grading of response to preoperative
chemotherapy, where scores 1 to 3
represent good tomoderate
response, 4 to 5 represent poor or
no response, and NA represents the
group where no preoperative
chemotherapy was given.
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period (53% in 2007-2012). The lymph node yieldwas higher
during the later calendar period than the earlier period. The
mediannumberof removednodesduring theentire studywas
14 (range, 0-52). The in-hospital postoperative mortality rate
was 3% (18 of 606 patients).
LymphNode Variables and 5-YearMortality
Therewasnodose-responseassociationbetweenlymphadenec-
tomy levels and 5-year mortality when 10 or 4 categories of
lymphadenectomywereassessed (Table2).ThecrudeHRsgen-
erally indicateda tendencyof increasedmortality,while thead-
justedHRs generally indicated the opposite. It wasmainly the
adjustment for T category and tumor differentiation that de-
creased theHRs in the adjustedmodel (data not shown).How-
ever,noneof theHRswas statistically significant (Table2).The
adjustedHR for all-cause 5-yearmortality in the highest quar-
tileof lymphadenectomy(21-52nodes)was0.86 (95%CI,0.63-
1.17)comparedwiththe lowestquartile (0-10nodes).Therewere
strongdose-responseassociationsbetweenthenumberofmeta-
staticnodesandmortality,aswellastheratioofpositiveandtotal
numberof lymphnodesandmortality (Table2).Thereweregen-
erallynomajordifferencesbetweenall-causeanddisease-specific
5-yearmortality (Table 2).
LymphNode Variables and T Category–Specific
5-YearMortality
Nostatistically significantassociationswere found in theanaly-
sis stratified for T categories (Table 3). However, the HRs for
all-cause 5-year mortality were slightly lower with more ex-
tensive lymphadenectomy inmore advanced tumors (T3-T4)
(HR, 0.80; 95%CI, 0.54-1.19 in the fourth quartile) compared
with the lessadvancedtumors (T0-T2) (HR,0.96;95%CI,0.58-
1.60 in the fourth quartile). Theprognostic influence ofmeta-
staticnodesandthe ratioofpositiveandtotalnumberof lymph
nodes were of similar strength in less- and more-advanced T
categories (Table 3). TheHRsof disease-specificmortality did
not differ much from those of all-cause mortality (Table 3).
LymphNode Variables and Calendar Period–Specific
5-YearMortality
In analyses stratified by the calendar periods 2000-2006 and
2007-2012,no statistically significant associationswere found
Table 2. All-Cause and Disease-Specific 5-YearMortality After Esophageal Cancer Surgery in Relation
to LymphNode Variables
Exposure
Patients,
No. (%)
5-y Mortality, HR (95% CI)
All Cause Disease Specific
Crude Adjusteda Crude Adjusteda
No. of nodes
(decentiles)
0-6 76 (13) 1 [Reference] 1 [Reference] 1 [Reference] 1 [Reference]
7-9 64 (11) 1.14 (0.71-1.82) 0.71 (0.44-1.16) 1.10 (0.65-1.87) 0.71 (0.41-1.23)
10-11 55 (9) 1.28 (0.80-2.05) 0.81 (0.49-1.32) 0.98 (0.56-1.73) 0.66 (0.37-1.19)
12-13 76 (13) 1.21 (0.77-1.89) 0.85 (0.54-1.35) 1.23 (0.75-2.02) 0.91 (0.55-1.53)
14 34 (6) 0.86 (0.46-1.58) 0.82 (0.44-1.52) 0.76 (0.37-1.55) 0.79 (0.38-1.64)
15-16 62 (10) 1.43 (0.91-2.25) 1.03 (0.65-1.64) 1.39 (0.84-2.31) 1.06 (0.63-1.79)
17-19 69 (11) 1.10 (0.70-1.74) 0.66 (0.41-1.06) 0.86 (0.50-1.49) 0.55 (0.31-0.97)
20-22 49 (8) 1.58 (0.98-2.57) 0.87 (0.52-1.43) 1.18 (0.66-2.11) 0.66 (0.36-1.22)
23-28 68 (11) 1.09 (0.69-1.73) 0.64 (0.39-1.04) 0.84 (0.49-1.46) 0.53 (0.30-0.95)
29-52 53 (9) 1.18 (0.72-1.92) 0.72 (0.43-1.20) 1.19 (0.69-2.04) 0.80 (0.45-1.41)
No. of nodes
(quartiles)
0-10 166 (27) 1 [Reference] 1 [Reference] 1 [Reference] 1 [Reference]
11-14 139 (23) 0.98 (0.72-1.35) 0.93 (0.67-1.30) 0.96 (0.67-1.39) 0.94 (0.65-1.38)
15-20 151 (25) 1.16 (0.86-1.56) 0.93 (0.68-1.26) 1.03 (0.73-1.47) 0.85 (0.59-1.22)
21-52 150 (25) 1.07 (0.79-1.44) 0.86 (0.63-1.17) 0.97 (0.68-1.39) 0.83 (0.57-1.20)
No. of metastatic
nodes
0 274 (45) 1 [Reference] 1 [Reference] 1 [Reference] 1 [Reference]
1-2 136 (22) 2.75 (2.02-3.75) 2.04 (1.49-2.80) 3.34 (2.30-4.85) 2.45 (1.67-3.59)
3-6 116 (19) 4.90 (3.61-6.64) 2.82 (2.03-3.92) 5.99 (4.15-8.65) 3.32 (2.24-4.94)
>6 80 (13) 6.58 (4.74-9.14) 3.48 (2.43-4.98) 8.04 (5.42-11.90) 3.84 (2.50-5.91)
Ratio of metastatic
to all nodes
0 274 (45) 1 [Reference] 1 [Reference] 1 [Reference] 1 [Reference]
0.02-0.14 111 (18) 2.56 (1.84-3.56) 1.84 (1.31-2.59) 3.01 (2.02-4.48) 2.23 (1.48-3.36)
0.15-0.37 111 (18) 3.98 (2.91-5.44) 2.46 (1.77-3.44) 4.81 (3.30-7.02) 2.79 (1.87-4.18)
>0.37 110 (18) 7.10 (5.25-9.61) 4.12 (2.95-5.77) 8.97 (6.24-12.90) 4.64 (3.11-6.95)
Abbreviation: HR, hazard ratio.
a Adjusted for age, pathological T
category, tumor differentiation,
margin status, response to
preoperative chemotherapy, and
calendar period.
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between total lymphadenectomy and all-cause or disease-
specific 5-year mortality (Table 4). The point HRs of total
lymphadenectomyduring the earlier periodwere slightly de-
creased, while the HRs were close to 1 in themore recent cal-
endar period (Table4). TheHRof all-causemortalitywas0.98
(95% CI, 0.57-1.66) in the highest quartile of lymphadenec-
tomy compared with the lowest during the more recent pe-
riod (2007-2012). The associations between the number of
metastatic nodes andmortality, aswell as the ratio of positive
and total number of lymph nodes and mortality, were stron-
ger during the later calendar period compared with the ear-
lier, and the disease-specific HRswere higher comparedwith
Table 4. Calendar Period–StratifiedMortality After Esophageal Cancer Surgery in 2000-2006 and 2007-2012 in Relation to LymphNode Variables
Exposure
Patients, No. (%)
5-y Mortality, Adjusted HR (95% CI)a
All Cause Disease Specific
Calendar Period
2000-2006 2007-2012 2000-2006 2007-2012 2000-2006 2007-2012
No. of nodes
(quartiles)
0-10 126 (34) 40 (17) 1 [Reference] 1 [Reference] 1 [Reference] 1 [Reference]
11-14 88 (24) 51 (21) 0.80 (0.54-1.19) 1.32 (0.74-2.35) 0.87 (0.56-1.35) 1.22 (0.58-2.59)
15-20 79 (22) 72 (30) 0.88 (0.59-1.29) 1.09 (0.64-1.87) 0.77 (0.49-1.21) 1.07 (0.54-2.13)
21-52 74 (20) 76 (32) 0.83 (0.56-1.24) 0.98 (0.57-1.66) 0.81 (0.52-1.28) 0.93 (0.47-1.84)
No. of metastatic
nodes
0 173 (47) 101 (42) 1 [Reference] 1 [Reference] 1 [Reference] 1 [Reference]
1-2 89 (24) 47 (20) 2.10 (1.43-3.07) 1.96 (1.12-3.41) 2.56 (1.65-3.99) 2.19 (1.03-4.65)
3-6 59 (16) 57 (24) 2.48 (1.64-3.75) 3.37 (2.02-5.62) 3.07 (1.92-4.93) 3.83 (1.92-7.66)
>6 46 (13) 34 (14) 2.76 (1.77-4.30) 5.10 (2.91-8.96) 3.15 (1.90-5.22) 6.00 (2.83-12.70)
Ratio of metastatic
to all nodes
0 173 (47) 101 (42) 1 [Reference] 1 [Reference] 1 [Reference] 1 [Reference]
0.02-0.14 64 (17) 47 (20) 1.97 (1.30-3.00) 1.78 (1.01-3.13) 2.41 (1.49-3.90) 2.03 (0.95-4.37)
0.15-0.37 59 (16) 52 (22) 1.94 (1.27-2.97) 3.50 (2.07-5.90) 2.46 (1.52-3.97) 3.66 (1.79-7.47)
>0.37 71 (19) 39 (16) 3.45 (2.32-5.13) 5.85 (3.40-10.10) 3.93 (2.49-6.22) 7.12 (3.47-14.60)
Abbreviation: HR, hazard ratio.
a Adjusted for age, pathological T category, tumor differentiation, margin status, response to preoperative chemotherapy, and calendar period.
Table 3. T Category–StratifiedMortality After Esophageal Cancer Surgery in Relation to LymphNode Variables
Exposure
Patients, No. (%)
5-y Mortality, Adjusted HR (95% CI)a
All Cause Disease Specific
T Category
T0-T2 T3-T4 T0-T2 T3-T4 T0-T2 T3-T4
No. of nodes (quartiles)
0-10 90 (29) 76 (26) 1 [Reference] 1 [Reference] 1 [Reference] 1 [Reference]
11-14 77 (25) 62 (21) 0.59 (0.33-1.04) 1.22 (0.82-1.82) 0.59 (0.29-1.19) 1.18 (0.75-1.85)
15-20 72 (23) 79 (27) 1.06 (0.64-1.76) 0.87 (0.59-1.28) 1.12 (0.60-2.10) 0.75 (0.48-1.18)
21-52 72 (23) 78 (26) 0.96 (0.58-1.60) 0.80 (0.54-1.19) 0.92 (0.48-1.76) 0.78 (0.50-1.23)
No. of metastatic nodes
0 192 (62) 82 (28) 1 [Reference] 1 [Reference] 1 [Reference] 1 [Reference]
1-2 69 (22) 67 (23) 1.69 (1.07-2.68) 2.41 (1.55-3.74) 1.91 (1.07-3.41) 2.95 (1.76-4.96)
3-6 35 (11) 81 (27) 2.86 (1.70-4.79) 2.97 (1.93-4.55) 3.25 (1.69-6.24) 3.59 (2.16-5.96)
>6 15 (5) 65 (22) 3.15 (1.61-6.17) 3.77 (2.42-5.86) 3.46 (1.50-7.96) 4.22 (2.50-7.13)
Ratio of metastatic to all nodes
0 192 (62) 82 (28) 1 [Reference] 1 [Reference] 1 [Reference] 1 [Reference]
0.02-0.14 60 (19) 51 (17) 1.55 (0.95-2.53) 2.15 (1.34-3.45) 2.02 (1.11-3.66) 2.43 (1.38-4.29)
0.15-0.37 41 (13) 70 (24) 2.84 (1.72-4.68) 2.39 (1.53-3.71) 2.54 (1.30-4.94) 3.02 (1.80-5.07)
>0.37 18 (6) 92 (31) 3.43 (1.87-6.31) 4.43 (2.92-6.74) 3.94 (1.89-8.21) 5.07 (3.08-8.35)
Abbreviation: HR, hazard ratio.
a Adjusted for age, pathological T category, tumor differentiation, margin status, response to preoperative chemotherapy, and calendar period.
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the all-cause HRs (Table 4). The highest quartiles of meta-
staticnodes (>6) and lymphnode ratio (>0.37)hadHRsof6.00
(95% CI, 2.83-12.7) and 7.12 (95% CI, 3.47-14.6), respectively,
compared with the corresponding lowest quartiles (0 and 0,
respectively).
LymphNode Variables and 5-YearMortality Following
Chemotherapy Response
The analyses stratified for preoperative chemotherapy re-
vealedno statistically significant associationsbetween theex-
tent of lymphadenectomy and mortality in any of the strati-
fication categories (Table 5). The HRs of mortality were close
to 1 in the nonchemotherapy group (all-cause HR, 1.03; 95%
CI, 0.56-1.90 and disease-specific HR, 0.97; 95% CI, 0.46-
2.06, comparing thehighest and lowest quartiles). TheHRsof
mortality tendedtobeslightlydecreased inbothgoodandpoor
responders topreoperative chemotherapy (Table 5). Thenum-
ber ofmetastatic nodes and the ratio ofmetastatic to all nodes
were both strongly associatedwith the risk formortality in all
3 chemotherapy categories but possibly even more so in the
group of poor responders (Table 5).
LymphNode Variables and 5-YearMortality Using Other
Reference Categories
Thestratified resultswhileusingother referencecategories are
presented in the eTable in the Supplement. There was no in-
fluence of the total number of removed nodes on all-cause or
disease-specificmortality,whilemetastatic nodes and the ra-
tio of metastatic and all nodes were strongly prognostic. An
additional analysis of the risk formortality inpatients inquar-
tiles of total lymphadenectomy in each of the 4 categories of
metastatic nodes revealed no patterns of any decreasedmor-
talitywithmoreextensive lymphadenectomy(datanotshown).
The propensity score analysis resulted in similar risk es-
timates as in the Cox regression analysis and therefore these
results are not presented.
Discussion
This study did not provide any support for the notion that
the extent of lymphadenectomy during surgery is a prognos-
tic factor in esophageal cancer. Although most point risk esti-
Table 5. Mortality Following Stratification for Chemotherapy Response in Patients Undergoing Esophageal Cancer Surgery in Relation
to LymphNode Variables
Exposure
Patients, No. (%)
5-y Mortality, Adjusted HR (95% CI)a
All Cause Disease Specific
Chemotherapy Response
Not
Applicableb Goodc Poord Not Applicableb Goodc Poord Not Applicableb Goodc Poord
No. of nodes
0-10 84 (39) 45 (25) 37 (17) 1 [Reference] 1 [Reference] 1 [Reference] 1 [Reference] 1 [Reference] 1 [Reference]
11-14 50 (23) 37 (21) 52 (24) 1.11
(0.64-1.95)
0.76
(0.37-1.57)
0.89
(0.52-1.50)
1.06
(0.54-2.06)
0.87
(0.41-1.87)
0.92
(0.49-1.71)
15-20 45 (21) 44 (25) 62 (29) 0.86
(0.48-1.54)
1.13
(0.60-2.14)
0.85
(0.51-1.40)
0.95
(0.49-1.85)
0.65
(0.28-1.50)
0.87
(0.48-1.58)
21-52 36 (17) 52 (29) 62 (29) 1.03
(0.56-1.90)
0.91
(0.50-1.67)
0.75
(0.45-1.24)
0.97
(0.46-2.06)
0.77
(0.38-1.54)
0.79
(0.44-1.44)
No. of
metastatic
nodes
0 132 (61) 92 (52) 50 (23) 1 [Reference] 1 [Reference] 1 [Reference] 1 [Reference] 1 [Reference] 1 [Reference]
1-2 34 (16) 49 (28) 53 (25) 1.02
(0.53-1.96)
2.64
(1.52-4.57)
2.48
(1.42-4.33)
1.69
(0.82-3.49)
2.93
(1.51-5.69)
2.59
(1.33-5.04)
3-6 33 (15) 26 (15) 57 (27) 3.22
(1.90-5.46)
4.30
(2.30-8.06)
2.30
(1.33-3.98)
3.99
(2.07-7.71)
4.87
(2.28-10.40)
2.55
(1.33-4.88)
>6 16 (7) 11 (6) 53 (25) 2.52
(1.28-4.96)
2.33
(0.96-5.68)
4.16
(2.40-7.20)
3.11
(1.37-7.05)
2.37
(0.80-7.06)
4.19
(2.19-8.04)
Ratio of
metastatic to
all nodes
0 132 (61) 92 (52) 50 (23) 1 [Reference] 1 [Reference] 1 [Reference] 1 [Reference] 1 [Reference] 1 [Reference]
0.02-0.14 24 (11) 42 (24) 45 (21) 0.89
(0.41-1.93)
2.49
(1.40-4.44)
2.10
(1.17-3.74)
1.57
(0.68-3.63)
2.77
(1.37-5.59)
2.20
(1.10-4.42)
0.15-0.37 32 (15) 26 (15) 53 (25) 2.41
(1.37-4.24)
4.17
(2.23-7.80)
2.14
(1.23-3.73)
2.96
(1.49-5.91)
4.78
(2.25-10.10)
2.23
(1.16-4.29)
>0.37 27 (13) 18 (10) 65 (31) 3.44
(1.96-6.04)
2.97
(1.44-6.10)
5.01
(2.92-8.57)
4.26
(2.15-8.44)
3.07
(1.29-7.28)
5.22
(2.76-9.87)
Abbreviation: HR, hazard ratio.
a Adjusted for age, pathological T category, tumor grade, margin status,
response to preoperative chemotherapy, and calendar period.
bNo chemotherapy given.
c Mandard score, 1-3.
dMandard score, 4-5.
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mates were decreased, the HRs were generally close to zero
effect and were particularly so for earlier T categories during
the more recent calendar period and in patients who did not
have preoperative chemotherapy. A higher number of meta-
static nodes and a higher ratio of positive and total number of
lymph nodes were, as expected, strong and dose-dependent
prognostic factors.
Somemethodological issues merit attention before mov-
ing on to discuss the findings of the present study. The
cohort design is the best available for studies specifically
addressing in detail the effects of the number of removed
lymph nodes. It is not feasible to randomize patients into
numerous categories of lymphadenectomy, and thus an
interventional study design was not an option for this pur-
pose. An additional strength was the exclusive inclusion of
patients operated on at a high-volume center, avoiding
potential bias resulting from differential surgical skills and
experience. A potential concern was that the pathological
assessment of removed lymph nodes was dependent on the
experience and interest of the responsible pathologist,
which could introduce exposure misclassification and dilu-
tions of associations. Therefore, a major strength was that
only highly specialized and dedicated upper gastrointestinal
pathologists performed these assessments in all patients
included in this study. The strong associations between
identified metastatic nodes and prognosis confirm the valid-
ity of the pathological nodal assessment. The outcome mor-
tality was completely and accurately assessed for all patients
because there were no losses to follow-up in this single-
center study, where all patients were followed up routinely
for at least 5 years following surgery. Bias from confounding
can never be excluded in an observational study; however,
the ability to adjust the results for all known strong prognos-
tic factors counteracts confounding. Because we could not
enlarge this study and had data from our previous study,11
we did not perform any sample-size calculations. Despite
the large sample, chance might have been a concern because
the power to verify weak associations was limited, particu-
larly in the stratified analyses. However, the overall results
showed no dose-response associations between total lymph-
adenectomy and mortality independent of various categori-
zations and stratifications, and the HRs were generally close
to unity, particularly during the more recent calendar period.
Finally, the multiethnic population of London suggests that
the results might be generalizable.
The lack of any clearly decreased mortality with more
extensive lymphadenectomy in this study supports the find-
ings of our previous study on this topic.11 That study
included 1044 patients from Sweden and found no decreased
mortality following a more extensive lymphadenectomy (HR,
1.00; 95% CI, 0.99-1.01 when the number of removed nodes
was analyzed as a continuous variable).11 These results chal-
lenge clinical guidelines recommending 2-field lymphad-
enectomy. The scientific evidence supporting more extensive
lymphadenectomy (2-field or even 3-field lymphadenec-
tomy) is limited and the topic is controversial.5-9 Our findings
are contradictory to those of a study using data from a con-
sortium of institutions, where a greater extent of lymphad-
enectomy was followed by better survival,17 and in a meta-
analysis comparing 2-field or even 3-field lymphadenectomy
that indicated better 5-year survival rates with 3-field
dissection.19 However, these findings were derived from
studies that might be hampered by stage migration issues
because a more extensive lymph node yield tends to result in
a more accurate assessment of metastatic nodes and thus
higher tumor stage. Moreover, confounding (eg, by the
known prognostic factor of surgeon volume) is a threat to
these studies20 because more experienced surgeons tend to
removemore nodes. In our study, all surgeons had a similarly
high annual volume of esophagectomies, which offers good
control of that potential confounding factor. Our results were
supported by some well-designed studies that found no sur-
vival difference between a more extensive lymphadenec-
tomy via transthoracic esophagectomy and a more limited
lymphadenectomy by a transhiatal approach, including a
large Dutch randomized clinical trial,21,22 our previous cohort
study,13 and a meta-analysis of 52 studies.23 Moreover, a ran-
domized clinical trial comparing 2-field with 3-field lymph-
adenectomy found no difference in survival.24
Thepresenceofmetastatic lymphnodes andahigh lymph
node ratio stronglypredicted survival in this study,whichcon-
firmed the results of previous studies.14 These findings high-
lighted the relevance of not only considering the presence or
absence ofmetastatic nodes, but also the number of involved
nodes in the prediction of prognosis.25 Thus, a limited level
of lymphadenectomyprovides a goodbasis for prognosis pre-
diction.
The results of this study indicated a need for further
research addressing the value of more and less extensive
lymphadenectomy (eg, a multisite interventional study com-
paring wide excision of lymph nodes vs standard excision).
Yet, it might be justified to compare the results of this study
with the developments in lymphadenectomy during surgery
for other tumors. In breast cancer, the previously advocated
more extensive lymphadenectomy did not improve
survival26 but increased morbidity.27 As a result, a less
extensive and more tailored approach to lymphadenectomy
has been adopted. A similar development has been seen in
the treatment of endometrial cancer.28,29 Among other gas-
trointestinal cancers, previous meta-analyses revealed no
evident survival benefits with extended lymphadenectomy
during surgery for pancreatic, gastric, or rectal cancers.30-33
It is possible that lymphadenectomy does not improve sur-
vival in esophageal cancer simply because positive nodes
represent a disseminated disease, while nonmetastatic
nodes do not need to be removed.
Conclusions
This cohort study, with adjustment for prognostic factors
from a dedicated esophageal cancer center, suggests that the
extent of lymphadenectomy does not influence survival
after surgery for esophageal cancer. These results challenge
current guidelines and need confirmation in further
research.
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